5 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 1 | Terminated 1 |
Follow Nausea: new trials by email Literature Review of Nausea trials Research Report on Nausea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) TAK-951, TAK-951 Placebo - Nausea and Vomitting | Phase 1 | Terminated | Takeda | 1 | 2022-03-02 | 2025-07-02 |
| Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis - Breast Cancer, Nausea | Phase 1 | Terminated | University of Southern California | 29 | 2012-09-04 | 2017-11-17 |
| Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain methadone hydrochloride, questionnaire administration, management of therapy complications - Nausea and Vomiting, Pain | Phase 1 | Terminated | NCIC Clinical Trials Group | 8 | 2010-06-17 | 2024-02-12 |
| Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 34 | 2008-08-01 | 2017-05-09 |
| Cyclophosphamide Drug Interaction Study In Cancer Patients Oral GW679769, IV Cyclophosphamide 500-700mg/m2 - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Terminated | GlaxoSmithKline | 25 | 2005-08-10 | 2017-11-17 |
Vomiting (4) · Breast Neoplasms (1) · Pain (1) · Sleep Wake Disorders (1)
Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Signs and Symptoms, Digestive (5) · Breast Diseases (1) · Mental Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
fosaprepitant (2) · Cyclophosphamide (1) · Granisetron (1) · Methadone (1) · Neoadjuvant Therapy (1) · casopitant (1)
GlaxoSmithKline (1) · NCIC Clinical Trials Group (1) · OHSU Knight Cancer Institute (1) · Takeda (1) · University of Southern California (1)
United States (4) · Canada (1) · New Zealand (1) · Sweden (1)
Agustin Garcia (1) · Bruno Gagnon, MD, MSC (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Ray Viola (1)
P30CA069533 (1)